Medigene AG: Medigene AG launches capital increase with subscription rights and backstop agreement

Planegg/Martinsried (pta032/22.04.2024/23:45 UTC+2)

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Executive Board together with the Supervisory Board have resolved to increase the share capital with subscription rights granted to shareholders and to carry out a private placement of the new shares not subscribed to in the subscription offer.

The Company plans to increase its share capital from EUR 24,562,658.00 by up to EUR 4,912,531.00 to up to EUR 29,475,189.00 by issuing up to 4,912,531 new no-par value registered shares with a pro rata amount of the share capital of EUR 1.00 and with full dividend rights from January 1, 2023.

The new shares will be offered to all shareholders for subscription. Over-subscription is permitted. Any unsubscribed new shares will be offered for purchase by way of a private placement to investors within the European Union. The subscription ratio is set at 5:1, i.e. five (5) old shares entitle the subscription to one (1) new share. Organized trading of subscription rights will be arranged. The subscription price for both the exercise of subscription rights and the private placement is EUR 1.20. The subscription period for the new shares begins on April 24, 2024 at 0:00 hours (CEST) and ends on May 7, 2024 at 24:00 hours (CEST). The new shares are to be admitted to trading on the Frankfurt Stock Exchange (Prime Standard) after they are issued. The capital increase will not require a prospectus. Details of the rights offering will be published in the Federal Gazette on April 23, 2024.

Members of Medigene AG's management and Supervisory Board intend to subscribe for new shares as part of the rights offering and the private placement. Within the framework of a backstop agreement, an investor has declared his commitment to Medigene to acquire unsubscribed new shares in an amount of up to EUR 3 million.

Medigene intends to use the gross proceeds of up to approximately EUR 5.9 million to fund its operating activities and to progress work for the clinical development of the Company's lead program, MDG1015.

NOT FOR DISTRIBUTION, TRANSMISSION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate